Evidence map›Paper›PMID 36233042›Full record

ArticleInternational journal of molecular sciences2022

Effects of

Hironobu Yagishita, Hideaki Kagaya, Mitsuru Saito, Kazuyuki Numakura, Ryohei Yamamoto, Ryuichiro Sagehashi, Tomonori Habuchi, Shigeru Satoh, Masatomo Miura

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hironobu YagishitaDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan.
Hideaki KagayaDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan.
Mitsuru SaitoDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
Kazuyuki NumakuraDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
Ryohei YamamotoDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
Ryuichiro SagehashiDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
Tomonori HabuchiDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
Shigeru SatohCenter for Kidney Disease and Transplantation, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan.
Masatomo MiuraDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan.ORCID 0000-0001-7120-2425
Akita University · JPAkita University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to evaluate the effects of NR1I2 (7635G>A and 8055C>T) and ABCB1 (1236C>T, 2677G>T/A, and 3435C>T) genetic polymorphisms on everolimus pharmacokinetics in 98 Japanese renal transplant patients. On day 15 after everolimus administration, blood samples were collected just prior to and 1, 2, 3, 4, 6, 9, and 12 h after administration. The dose-adjusted area under the blood concentration−time curve (AUC0-12) of everolimus was significantly lower in patients with the NR1I2 8055C/C genotype than in those with other genotypes (p = 0.022) and was significantly higher in male patients than female patients (p = 0.045). Significant correlations between the dose-adjusted AUC0-12 of everolimus and age (p = 0.001), aspartate transaminase (p = 0.001), and alanine transaminase (p = 0.005) were found. In multivariate analysis, aging (p = 0.008) and higher alanine transaminase levels (p = 0.032) were independently predictive of a higher dose-adjusted everolimus AUC0-12. Aging and hepatic dysfunction in patients may need to be considered when evaluating dose reductions in everolimus. In renal transplant patients, management using everolimus blood concentrations after administration may be more important than analysis of NR1I2 8055C>T polymorphism before administration.

Indexed as

ATP Binding Cassette Transporter, Subfamily BEverolimusKidney TransplantationPregnane X ReceptorAlanine TransaminaseAspartate AminotransferasesCytochrome P-450 CYP3AFemaleGenotypeHumansImmunosuppressive AgentsJapanMalePolymorphism, Single NucleotideABCB1 protein, humanAlanine TransaminaseAspartate AminotransferasesATP Binding Cassette Transporter, Subfamily BCytochrome P-450 CYP3AEverolimusImmunosuppressive AgentsNR1I2 protein, humanPregnane X ReceptoreverolimusP-glycoproteinpolymorphismpregnane X-receptor

Identifiers

PMID36233042
PMCPMC9570057
OpenAlexW4303699998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.